BioCryst joins Clearside Biomedical for diabetic eye disease
| BCRX Stock | USD 7.49 0.03 0.40% |
Slightly above 54% of BioCryst Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding BioCryst Pharmaceuticals suggests that many traders are impartial. BioCryst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, BioCryst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
BioCryst |
BioCryst Pharmaceuticals and Clearside Biomedical ink a licensing deal to develop a more effective treatment for diabetic macular edema. Read more here.
Read at seekingalpha.com
 |
BioCryst Pharmaceuticals Fundamental Analysis
We analyze BioCryst Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
BioCryst Pharmaceuticals is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
BioCryst Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioCryst Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of BioCryst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
BioCryst Pharmaceuticals Related Equities
| XFOR | X4 Pharmaceuticals | 13.85 | ||||
| AXSM | Axsome Therapeutics | 4.27 | ||||
| APLS | Apellis Pharmaceuticals | 1.42 | ||||
| BPMC | Blueprint Medicines | 1.14 | ||||
| PDSB | PDS Biotechnology | 1.03 | ||||
| AVXL | Anavex Life | 0.33 | ||||
| DAWN | Day One | 0.16 | ||||
| IMUX | Immunic | 0.00 | ||||
| KZR | Kezar Life | 0.91 | ||||
| VKTX | Viking Therapeutics | 1.12 | ||||
| MCRB | Seres Therapeutics | 1.12 | ||||
| ATRA | Atara Biotherapeutics | 1.52 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.58 | ||||
| INMB | INmune Bio | 1.97 | ||||
| BIVI | Biovie | 1.97 | ||||
| TGTX | TG Therapeutics | 2.41 | ||||
| SAVA | Cassava Sciences | 4.14 | ||||
| CGTX | Cognition Therapeutics | 6.25 | ||||
| PIRS | Pieris Pharmaceuticals | 15.69 |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.